This study investigates the relationship between cytomegalovirus and ovarian cancer through patient-reported symptoms after receiving treatment. Information from this study may help researchers better understand the role of cytomegalovirus on patient symptoms and overall outcomes in patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03921658.
PRIMARY OBJECTIVES:
I. Determine the relationship between cytomegalovirus (CMV) and ovarian cancer patient-reported symptoms post-treatment.
II. Characterize the changes in CMV and C-reactive protein (CRP) levels following chemotherapy and their association with patient symptoms and outcomes.
OUTLINE:
Patients who have completed initial chemotherapy undergo collection of a blood sample and complete a survey. Patients who are newly diagnosed with ovarian cancer undergo collection of blood samples and complete surveys prior to the start of chemotherapy, immediately after completion of chemotherapy, and 6 months after completion of chemotherapy.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationUniversity of Minnesota/Masonic Cancer Center
Principal InvestigatorRachel I Vogel
